Acute Ischemic Stroke – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 8 PAGES: 152

More Info
									        Acute Ischemic Stroke – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1753IDB
                                                                                           Publication Date: February 2012




Acute Ischemic Stroke – Pipeline Review, H1 2012                                           GMDHC1753IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Acute Ischemic Stroke – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 9
    List of Figures .............................................................................................................................................................................. 10
Introduction....................................................................................................................................................................................... 11
    Global Markets Direct Report Coverage ...................................................................................................................................... 11
Acute Ischemic Stroke Overview ...................................................................................................................................................... 12
Therapeutics Development............................................................................................................................................................... 13
    An Overview of Pipeline Products for Acute Ischemic Stroke ...................................................................................................... 13
Acute Ischemic Stroke Therapeutics under Development by Companies ........................................................................................ 15
Acute Ischemic Stroke Therapeutics under Investigation by Universities/Institutes ......................................................................... 18
Late Stage Products ......................................................................................................................................................................... 21
    Comparative Analysis .................................................................................................................................................................. 21
Mid Clinical Stage Products.............................................................................................................................................................. 22
    Comparative Analysis .................................................................................................................................................................. 22
Early Clinical Stage Products ........................................................................................................................................................... 23
    Comparative Analysis .................................................................................................................................................................. 23
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 24
    Comparative Analysis .................................................................................................................................................................. 24
Acute Ischemic Stroke Therapeutics – Products under Development by Companies ...................................................................... 25
Acute Ischemic Stroke Therapeutics – Products under Investigation by Universities/Institutes ....................................................... 26
Companies Involved in Acute Ischemic Stroke Therapeutics Development ..................................................................................... 27
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 27
    Sanofi-Aventis ............................................................................................................................................................................. 28
    Athersys, Inc. ............................................................................................................................................................................... 29
    Aldagen, Inc................................................................................................................................................................................. 30
    Henry Ford Health System .......................................................................................................................................................... 31
    H Lundbeck A/S........................................................................................................................................................................... 32
    Mitsubishi Tanabe Pharma Corporation ...................................................................................................................................... 33
    Pfizer Inc...................................................................................................................................................................................... 34
    Talecris Biotherapeutics Holdings Corp....................................................................................................................................... 35
    Celgene Corporation ................................................................................................................................................................... 36
    Vernalis plc .................................................................................................................................................................................. 37
    RegeneRx Biopharmaceuticals, Inc............................................................................................................................................. 38
    SYGNIS Pharma AG ................................................................................................................................................................... 39
    Torrent Pharmaceuticals Limited ................................................................................................................................................. 40
    ThromboGenics NV ..................................................................................................................................................................... 41
    Stem Cell Therapeutics Corp....................................................................................................................................................... 42
    D-Pharm Ltd. ............................................................................................................................................................................... 43
    BioMAS Ltd.................................................................................................................................................................................. 44
    Angion Biomedica Corp. .............................................................................................................................................................. 45
    Stemedica Cell Technologies, Inc. .............................................................................................................................................. 46
    SanBio, Inc. ................................................................................................................................................................................. 47



Acute Ischemic Stroke – Pipeline Review, H1 2012                                                                                            GMDHC1753IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Acute Ischemic Stroke – Pipeline Review, H1 2012




    M's Science Corporation.............................................................................................................................................................. 48
    Thrombotech Technologies, Ltd. ................................................................................................................................................. 49
Acute Ischemic Stroke – Therapeutics Assessment......................................................................................................................... 50
    Assessment by Monotherapy Products ....................................................................................................................................... 50
    Assessment by Combination Products ........................................................................................................................................ 51
    Assessment by Route of Administration ...................................................................................................................................... 52
    Assessment by Molecule Type .................................................................................................................................................... 54
Drug Profiles..................................................................................................................................................................................... 57
    Desmoteplase - Drug Profile........................................................................................................................................................ 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    Desmoteplase - Drug Profile........................................................................................................................................................ 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    Radicut - Drug Profile .................................................................................................................................................................. 61
        Product Description................................................................................................................................................................. 61
        Mechanism of Action ............................................................................................................................................................... 61
        R&D Progress ......................................................................................................................................................................... 61
    ILS-920 - Drug Profile .................................................................................................................................................................. 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    MultiStem - Drug Profile .............................................................................................................................................................. 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    PDA001 - Drug Profile ................................................................................................................................................................. 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    MP-124 - Drug Profile .................................................................................................................................................................. 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    Ocriplasmin - Drug Profile ........................................................................................................................................................... 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    DP-b99 - Drug Profile .................................................................................................................................................................. 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69


Acute Ischemic Stroke – Pipeline Review, H1 2012                                                                                           GMDHC1753IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Acute Ischemic Stroke – Pipeline Review, H1 2012




    AX200 - Drug Profile.................................................................................................................................................................... 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    RGN-352 - Drug Profile ............................................................................................................................................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    BB3 - Drug Profile........................................................................................................................................................................ 74
        Product Description................................................................................................................................................................. 74
        Mechanism of Action ............................................................................................................................................................... 74
        R&D Progress ......................................................................................................................................................................... 74
    NTx-265 - Drug Profile ................................................................................................................................................................. 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ...............
								
To top